Cencora Inc (COR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite the recent price decline, the company's strong financial performance, positive analyst sentiment, and hedge fund buying activity indicate long-term growth potential.
The stock's MACD is negative and expanding, indicating bearish momentum in the short term. RSI is neutral at 35.268, showing no clear overbought or oversold condition. However, the moving averages (SMA_5 > SMA_20 > SMA_200) are bullish, suggesting an overall upward trend in the long term. The stock is near its support level at $355.08, which could provide a good entry point.

Hedge funds are significantly increasing their positions, with a 2472.49% rise in buying activity.
Analysts have consistently raised price targets, with the latest targets ranging from $400 to $440, reflecting strong confidence in the company's growth.
The company has cleared risks related to Walgreens and government drug pricing, opening up multi-year growth opportunities.
Strong Q1 2026 financial performance, with revenue, net income, EPS, and gross margin all showing significant YoY growth.
The stock has experienced a recent price decline of -2.42% in the regular market and -0.54% in pre-market trading, which could indicate short-term bearish sentiment.
The MACD indicator is showing bearish momentum.
In Q1 2026, Cencora reported a 5.45% YoY increase in revenue to $85.93 billion, a 14.54% YoY increase in net income to $559.65 million, and a 14.80% YoY increase in EPS to $2.87. Gross margin also improved by 17.63% YoY to 3.27%, indicating strong operational efficiency and profitability.
Analysts are overwhelmingly positive on Cencora, with multiple upgrades and raised price targets. Recent ratings include Overweight and Buy, with price targets ranging from $400 to $440. Analysts highlight the company's leadership in specialty distribution, strategic acquisitions, and cleared risks as key drivers of growth.